|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006142,
umls-concept:C0008976,
umls-concept:C0010583,
umls-concept:C0013089,
umls-concept:C0016360,
umls-concept:C0034037,
umls-concept:C0043210,
umls-concept:C0144576,
umls-concept:C0205179,
umls-concept:C0443252,
umls-concept:C0936012,
umls-concept:C1704324,
umls-concept:C1708063
|
|
pubmed:issue |
8-9
|
|
pubmed:dateCreated |
2009-9-11
|
|
pubmed:abstractText |
The aim of this study was to perform an independent review of the efficacy data and to determine whether the efficacy difference observed in a phase III randomised clinical trial that compared doxorubicin plus paclitaxel (AT) versus fluorouracil/doxorubicin/cyclophosphamide (FAC) in first-line chemotherapy of metastatic breast cancer was maintained after a longer follow-up period.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1423-0240
|
|
pubmed:author |
pubmed-author:AloeAlessandraA,
pubmed-author:AstierLudovicL,
pubmed-author:BerzinsJurisJ,
pubmed-author:BiganzoliLauraL,
pubmed-author:GorbunovaVeraV,
pubmed-author:JassemJacekJ,
pubmed-author:JelicSvetislavS,
pubmed-author:MunierStephaneS,
pubmed-author:NagykalnaiThomasT,
pubmed-author:PienkowskiTadeuszT,
pubmed-author:PluzanskaAnnaA
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
32
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
468-72
|
|
pubmed:meshHeading |
pubmed-meshheading:19745590-Adult,
pubmed-meshheading:19745590-Aged,
pubmed-meshheading:19745590-Aged, 80 and over,
pubmed-meshheading:19745590-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19745590-Breast Neoplasms,
pubmed-meshheading:19745590-Cyclophosphamide,
pubmed-meshheading:19745590-Doxorubicin,
pubmed-meshheading:19745590-Europe,
pubmed-meshheading:19745590-Female,
pubmed-meshheading:19745590-Fluorouracil,
pubmed-meshheading:19745590-Humans,
pubmed-meshheading:19745590-Middle Aged,
pubmed-meshheading:19745590-Paclitaxel,
pubmed-meshheading:19745590-Prevalence,
pubmed-meshheading:19745590-Survival Analysis,
pubmed-meshheading:19745590-Survival Rate,
pubmed-meshheading:19745590-Treatment Outcome
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Doxorubicin and paclitaxel versus fluorouracil, doxorubicin and cyclophosphamide as first-line therapy for women with advanced breast cancer: long-term analysis of the previously published trial.
|
|
pubmed:affiliation |
Dept. of Oncology and Radiotherapy, Medical University of Gda?sk, Gdansk, Poland. jjassem@amg.gda.pl
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase III
|
